Effects of 4-MU (1 mM) and/or CBP (100 μM) treatment on apoptosis were measured by using a caspase 3/7 cleavage assay in primary serous ovarian cancer cells. This evidence concerns the gene CASP3 and ovarian serous adenocarcinoma.